SCHEMBL571076

SCHEMBL571076

O=Cc1ccc(C2CCN(C(=O)C(F)(F)F)CC2)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RY14 Q15391 1/20 0.45
KDM1A O60341 1/20 0.43
NAMPT P43490 2/20 0.40
RIPK1 Q13546 1/20 0.40
TLR9 Q9NR96 1/20 0.39
TLR8 Q9NR97 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
EPHX2 P34913 2/20 0.39
EPHX1 P07099 1/20 0.39
RBP4 P02753 2/20 0.39
QDPR P09417 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CCR2 P41597 3/20 0.37
LIPE Q05469 1/20 0.37
FAAH O00519 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2452371 0.82 KDM1A (0.48) P2RY14KDM1ANAMPTRIPK1TLR9
SCHEMBL8414100 0.82 P2RY14 (0.47) P2RY14KDM1ANAMPTRIPK1TLR9
SCHEMBL20705482 0.82 RAB9A (0.50) P2RY14KDM1ANAMPTTLR9TLR8
SCHEMBL571141 0.81 KDM1A (0.60) P2RY14KDM1ARIPK1RBP4NPC1
SCHEMBL19371919 0.81 NPC1 (0.44) NAMPTQDPRNPC1MAPTHPGD
SCHEMBL15254117 0.81 P2RY14 (0.56) P2RY14KDM1ANAMPTRIPK1TLR9
SCHEMBL20124850 0.79 P2RY14 (0.45) P2RY14KDM1ANAMPTRIPK1TLR9
SCHEMBL571736 0.79 P2RY14 (0.47) P2RY14KDM1ANAMPTRIPK1TLR9
SCHEMBL6126281 0.79 P2RY14 (0.45) P2RY14KDM1ANAMPTRIPK1TLR9
SCHEMBL10243175 0.79 MAPT (0.50) P2RY14KDM1ANAMPTRIPK1TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12319683-B2 Azabenzimidazole compounds and pharmaceutical NIPPON SHINYAKU CO., LTD. (JP) 2025-06-03 US disclosed
EP-3792260-B1 AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL NIPPON SHINYAKU CO LTD (JP) 2024-09-11 EP disclosed
CN-112368282-B Azabenzimidazole compounds and medicaments 日本新药株式会社 2023-10-13 CN disclosed
US-20210371412-A1 AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL NIPPON SHINYAKU CO., LTD. (JP) 2021-12-02 US disclosed
EP-3792260-A1 AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL Nippon Shinyaku Co., Ltd. (JP) 2021-03-17 EP disclosed
CN-112368282-A Azabenzimidazole compounds and pharmaceuticals 日本新药株式会社 2021-02-12 CN disclosed
US-10196373-B2 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2019-02-05 US disclosed
US-10196373-B2 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2019-02-05 US disclosed
EP-2900643-B1 QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS MERCK PATENT GMBH (DE) 2017-09-27 EP disclosed
US-9388142-B2 Quinazolinone derivatives as PARP inhibitors MERCK PATENT GMBH (DE) 2016-07-12 US disclosed
EP-2640724-A1 NOVEL INDOLIZINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-09-25 EP disclosed
US-20130225621-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN UNIVERSITY OF TORONTO MISSISSAUGA (CA) 2013-08-29 US disclosed
US-20130225621-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN UNIVERSITY OF TORONTO MISSISSAUGA (CA) 2013-08-29 US disclosed
EP-2600860-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEINS University of Central Florida Research Foundation, Inc. (US) 2013-06-12 EP disclosed
WO-2012066234-A9 NOVEL INDOLIZINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-11-01 WO disclosed
WO-2012066234-A1 NOVEL INDOLIZINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-05-24 WO disclosed
WO-2012018868-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEINS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-02-09 WO disclosed
WO-2012018868-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEINS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-02-09 WO disclosed
CN-1094035-A Carboxylic acid derivative contains pharmaceutical composition of these compounds and preparation method thereof THOMAE GMBH DR K (DE) 1994-10-26 CN disclosed
EP-0604800-A1 4- 4- 4-(carboxyalkyl)-phenyl amino carbonyl -phenyl -piperedines as aggregation inhibitors Dr. Karl Thomae GmbH (DE) 1994-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371412-A1 AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL PAM, CHRM3, AZI2 P2RY14 65/4885KDM1A 558/4885NAMPT 512/4885
US-20130225621-A1 SUBSTITUTED 2-HYDROXY-4-(2-(PHENYLSULFONAMIDO)ACETAMIDO)BENZOIC ACID ANALOGS AS INHIBITORS OF STAT PROTEIN STAT3, STAT1, STAT4 P2RY14 3048/4885KDM1A 2433/4885NAMPT 2249/4885
US-10196373-B2 Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein STAT3, STAT1, STAT4 P2RY14 3048/4885KDM1A 2433/4885NAMPT 2249/4885
US-12319683-B2 Azabenzimidazole compounds and pharmaceutical PAM, CHRM3, AZI2 P2RY14 65/4885KDM1A 558/4885NAMPT 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.